SLC13A5-IN-1 manufacturers
- SLC13A5-IN-1
-
- $98.00
-
2026-09-10
- CAS:2227548-95-8
- Purity: 99.67%
- Supply Ability: 10g
- SLC13A5-IN-1
-
- $98.00
-
2026-07-14
- CAS:2227548-95-8
- Purity: 99.67%
- Supply Ability: 10g
|
| | SLC13A5-IN-1 Basic information |
| Product Name: | SLC13A5-IN-1 | | Synonyms: | SLC13A5-IN-1;N-[(4-chlorophenyl)methyl]-1-(3,5-dichlorobenzen esulfonyl)piperidine-4-carboxamide;4-Piperidinecarboxamide, N-[(4-chlorophenyl)methyl]-1-[(3,5-dichlorophenyl)sulfonyl]-;hSLC3A5,metabolic,SLC-13A5-IN-1,SLC13A5IN1,Inhibitor,Citrate,SLC13A5,cardiovascular,inhibit,disease,Sodium Channel,Uptake,Na channels,Na+ channels,SLC13A5 IN 1;N-(4-Chlorobenzyl)-1-((3,5-dichlorophenyl)sulfonyl)piperidine-4-carboxamide;SLC13A5-IN-1, 10 mM in DMSO | | CAS: | 2227548-95-8 | | MF: | C19H19Cl3N2O3S | | MW: | 461.79 | | EINECS: | | | Product Categories: | | | Mol File: | 2227548-95-8.mol |  |
| | SLC13A5-IN-1 Chemical Properties |
| density | 1.436±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 7 mg/mL (15.16 mM);Ethanol: Insoluble | | pka | 14.79±0.20(Predicted) | | form | Solid | | color | White to off-white | | Water Solubility | Water: Insoluble |
| | SLC13A5-IN-1 Usage And Synthesis |
| Uses | SLC13A5-IN-1 is a selective sodium-citrate co-transporter (SLC13A5) inhibitor. SLC13A5-IN-1 completely blocksthe uptake of14C-citrate with an IC50 value of 0.022 μM in HepG2 cells. SLC13A5-IN-1 has the potential for the treatment of metabolic and/or cardiovascular diseases. SLC13A5-IN-1 is extracted from patent WO2018104220A1, Compound I-5[1]. | | References | [1] Joerg Kley, et al. Sulfonamides as inhibitors of the uptake of extracellular citrate. Patent WO2018104220A1 |
| | SLC13A5-IN-1 Preparation Products And Raw materials |
|